Ciclesonide

Last reviewed: May 1st, 2020

There is insufficient evidence to support use of Ciclesonide for treatment of patients infected with SARS-CoV-2.

Peer-reviewed Studies

  1. Japanese report in three patients referenced in peer-reviewed studies and news reports but appears to be no longer available. Unsure if report was peer-reviewed. “Asthma drug seems effective for COVID-19 pneumonia.” (https://www3.nhk.or.jp/nhkworld/en/news/20200303_20/); [Human, Observational SARS CoV-2, Effective]

  2. Matsuyama S., Kawase M., Nao N., et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv. 2020. (https://www.biorxiv.org/content/biorxiv/early/2020/03/12/2020.03.11.987016.full.pdf); [Preclinical, In Vitro SARS CoV-1/2, Effective]

  3. Jeon S., Ko M., Lee J., et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. bioRxiv. 2020. (https://www.biorxiv.org/content/10.1101/2020.03.20.999730v3.full.pdf); [Preclinical, In Vitro SARS CoV-1/2, Effective]

  4. Ko M., Chang S.Y., Byun S.Y., et al. Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19. bioRxiv. 2020. (https://www.biorxiv.org/content/10.1101/2020.02.25.965582v2.full.pdf); [Preclinical, In Vitro SARS CoV-1/2, Effective]